<!DOCTYPE html>
<html>
    <head>
        <title>ONALABS QMS : OV Part F: Pre-Clinical Information</title>
        <link rel="stylesheet" href="styles/site.css" type="text/css" />
        <META http-equiv="Content-Type" content="text/html; charset=UTF-8">
    </head>

    <body class="theme-default aui-theme-default">
        <div id="page">
            <div id="main" class="aui-page-panel">
                <div id="main-header">
                    <div id="breadcrumb-section">
                        <ol id="breadcrumbs">
                            <li class="first">
                                <span><a href="index.html">ONALABS QMS</a></span>
                            </li>
                                                    <li>
                                <span><a href="OV-ONAVITAL-MDR-Product-Technical-File_3342337.html">OV ONAVITAL MDR Product Technical File</a></span>
                            </li>
                                                </ol>
                    </div>
                    <h1 id="title-heading" class="pagetitle">
                                                <span id="title-text">
                            ONALABS QMS : OV Part F: Pre-Clinical Information
                        </span>
                    </h1>
                </div>

                <div id="content" class="view">
                    <div class="page-metadata">
                            
        
    
        
    
        
        
            Created by <span class='author'> Richard Bunney</span>, last modified by <span class='editor'> Jaime Punter</span> on May 20, 2025
                        </div>
                    <div id="main-content" class="wiki-content group">
                    <p><strong>Product Verification and Validation</strong></p><p><span class="status-macro aui-lozenge aui-lozenge-visual-refresh aui-lozenge-error">CONFIDENTIAL</span> <span class="status-macro aui-lozenge aui-lozenge-visual-refresh aui-lozenge-error">UNCONTROLLED IF PRINTED</span></p><p>Owner: Jaime Punter, CTO and Quality Representative</p><div class="ap-container" id="ap-com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro3839754171192700469">

  <div class="ap-content " id="embedded-com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro3839754171192700469"></div>
  <script nonce="528a568c4bd9f0fff5a3a25050ba0fb5" class="ap-iframe-body-script">
  (function(){
    var data = {
    "addon_key":"com.automation-consultants.accloud.approvalmacro",
    "uniqueKey":"com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro3839754171192700469",
    "key":"ApprovalsStatusMacro",
     "moduleType":"dynamicContentMacros",      "moduleLocation":"content",         "cp":"/wiki",
            "general":"",
    "w":"",
    "h":"",
    "url":"https://ac-cloud.com/approvalmacro/macro/page-status/display?xdm_e=https%3A%2F%2Fonalabs.atlassian.net&xdm_c=channel-com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro3839754171192700469&cp=%2Fwiki&xdm_deprecated_addon_key_do_not_use=com.automation-consultants.accloud.approvalmacro&lic=active&cv=1000.0.0-c58bc7260813&traceId=bfc40a7fbc2fc9007c8017ae5514f1e4&spanId=4627ec7306650707&traceSampled=0&jwt=eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJzdWIiOiI2MDU0OTY2Yjk0ZDdiOTAwNjkwMmRkMWUiLCJxc2giOiIxNDQ2ZDA3ODNiNTBhZDhmYzRmZjY2MTVkOGViOWU0ZDRmNGVjYjgzMjQxZTY0NjYyMjUzNTUzOGUwYjcyYzhmIiwiaXNzIjoiNzdjODA3YTAtMmNjNy0zZWVjLWEzNDItOWQzYzYyZjUwZWE0IiwiY29udGV4dCI6e30sImV4cCI6MTc1MTI5NTU4MSwiaWF0IjoxNzUxMjk1NDAxfQ.LbJwOmoOJsRttWHnC_LW_yxuWgeAw1yl_crLUXw6zLg",
     "contextJwt": "eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJzdWIiOiI2MDU0OTY2Yjk0ZDdiOTAwNjkwMmRkMWUiLCJxc2giOiJjb250ZXh0LXFzaCIsImlzcyI6Ijc3YzgwN2EwLTJjYzctM2VlYy1hMzQyLTlkM2M2MmY1MGVhNCIsImNvbnRleHQiOnsibGljZW5zZSI6eyJhY3RpdmUiOnRydWV9LCJjb25mbHVlbmNlIjp7ImVkaXRvciI6eyJ2ZXJzaW9uIjoidjIifSwibWFjcm8iOnsib3V0cHV0VHlwZSI6Imh0bWxfZXhwb3J0IiwiaGFzaCI6ImFlODY2OGJhLTMxYTItNDkwMC05M2NhLTM2NzZiNmYzNWM1MSIsImlkIjoiYWU4NjY4YmEtMzFhMi00OTAwLTkzY2EtMzY3NmI2ZjM1YzUxIn0sInRyYWNpbmciOnsidHJhY2VJZCI6ImJmYzQwYTdmYmMyZmM5MDA3YzgwMTdhZTU1MTRmMWU0Iiwic3BhbklkIjoiNDYyN2VjNzMwNjY1MDcwNyIsInNhbXBsZWQiOiIwIn0sImNvbnRlbnQiOnsidHlwZSI6InBhZ2UiLCJ2ZXJzaW9uIjoiNCIsImlkIjoiMzM0Mjc4NyJ9LCJzcGFjZSI6eyJrZXkiOiJPTkFMQUJTUU1TIiwiaWQiOiIyNzUyNTEyIn19LCJ1cmwiOnsiZGlzcGxheVVybCI6Imh0dHBzOlwvXC9vbmFsYWJzLmF0bGFzc2lhbi5uZXRcL3dpa2kifX0sImV4cCI6MTc1MTI5NjMwMSwiaWF0IjoxNzUxMjk1NDAxfQ.c7KLJ2HKL9auX0FBJ8uP6ihEa376mwC6Qkm3OYhgk9Q",    "structuredContext": "{\"license\":{\"active\":true},\"confluence\":{\"editor\":{\"version\":\"v2\"},\"macro\":{\"outputType\":\"html_export\",\"hash\":\"ae8668ba-31a2-4900-93ca-3676b6f35c51\",\"id\":\"ae8668ba-31a2-4900-93ca-3676b6f35c51\"},\"tracing\":{\"traceId\":\"bfc40a7fbc2fc9007c8017ae5514f1e4\",\"spanId\":\"4627ec7306650707\",\"sampled\":\"0\"},\"content\":{\"type\":\"page\",\"version\":\"4\",\"id\":\"3342787\"},\"space\":{\"key\":\"ONALABSQMS\",\"id\":\"2752512\"}},\"url\":{\"displayUrl\":\"https://onalabs.atlassian.net/wiki\"}}",
    "contentClassifier":"content",
    "productCtx":"{\"page.id\":\"3342787\",\"macro.hash\":\"ae8668ba-31a2-4900-93ca-3676b6f35c51\",\"space.key\":\"ONALABSQMS\",\"tracing.sampled\":\"0\",\"page.type\":\"page\",\"content.version\":\"4\",\"page.title\":\"OV Part F: Pre-Clinical Information\",\"macro.localId\":\"0c3f9906-444c-40f8-bfa0-4e2e3137853d\",\"macro.body\":\"\",\": = | RAW | = :\":null,\"space.id\":\"2752512\",\"macro.truncated\":\"false\",\"content.type\":\"page\",\"output.type\":\"html_export\",\"page.version\":\"4\",\"macro.fragmentLocalId\":\"\",\"content.id\":\"3342787\",\"tracing.traceId\":\"bfc40a7fbc2fc9007c8017ae5514f1e4\",\"macro.id\":\"ae8668ba-31a2-4900-93ca-3676b6f35c51\",\"tracing.spanId\":\"4627ec7306650707\",\"user.isExternalCollaborator\":\"false\",\"editor.version\":\"v2\"}",
    "timeZone":"GB",
    "origin":"https://ac-cloud.com",
    "hostOrigin":"https://onalabs.atlassian.net",
    "sandbox":"allow-downloads allow-forms allow-modals allow-popups allow-popups-to-escape-sandbox allow-scripts allow-same-origin allow-top-navigation-by-user-activation allow-storage-access-by-user-activation",    "pearApp":"true",        "apiMigrations": {
        "gdpr": true
    }
}
;
    if(window.AP && window.AP.subCreate) {
      window._AP.appendConnectAddon(data);
    } else {
      require(['ac/create'], function(create){
        create.appendConnectAddon(data);
      });
    }

    // For Confluence App Analytics. This code works in conjunction with CFE's ConnectSupport.js.
    // Here, we add a listener to the initial HTML page that stores events if the ConnectSupport component
    // has not mounted yet. In CFE, we process the missed event data and disable this initial listener.
    const __MAX_EVENT_ARRAY_SIZE__ = 20;
    const connectAppAnalytics = "ecosystem.confluence.connect.analytics";
    window.connectHost && window.connectHost.onIframeEstablished((eventData) => {
      if (!window.__CONFLUENCE_CONNECT_SUPPORT_LOADED__) {
        let events = JSON.parse(window.localStorage.getItem(connectAppAnalytics)) || [];
        if (events.length >= __MAX_EVENT_ARRAY_SIZE__) {
          events.shift();
        }
        events.push(eventData);
        window.localStorage.setItem(connectAppAnalytics, JSON.stringify(events));
      }
    });

  }());
</script>

</div>
<p /><ul><li><p><a class="external-link" href="https://tinnisoothe.atlassian.net/wiki/spaces/TF/pages/3833857/Device+Version+History#1.-Purpose" rel="nofollow">1. Purpose</a></p></li><li><p><a class="external-link" href="https://tinnisoothe.atlassian.net/wiki/spaces/TF/pages/3833857/Device+Version+History#2.-Version-History" rel="nofollow">2. Version History</a></p></li><li><p><a class="external-link" href="https://tinnisoothe.atlassian.net/wiki/spaces/TF/pages/3833857/Device+Version+History#3.-Document-Distribution" rel="nofollow">3. Document Distribution</a></p></li></ul><h3 id="OVPartF:Pre-ClinicalInformation-1.Purpose">1. Purpose</h3><p>To record and maintain a record of product verification and validation in accordance with regulation (EU) 2017/745 of the European Parliament and of the Council.</p><h3 id="OVPartF:Pre-ClinicalInformation-2.DesignandManufacturingInformation">2. Design and Manufacturing Information</h3><div class="table-wrap"><table data-layout="wide" data-local-id="27414e48-784a-4975-9f81-a7fad940f932" class="confluenceTable"><colgroup><col style="width: 229.0px;"/><col style="width: 384.0px;"/><col style="width: 364.0px;"/></colgroup><tbody><tr><td data-highlight-colour="#ffa9a4" class="confluenceTd"><p><strong>Section Title / Item</strong></p></td><td data-highlight-colour="#ffa9a4" class="confluenceTd"><p><strong>Additional Guidance</strong></p></td><td data-highlight-colour="#ffa9a4" class="confluenceTd"><p><strong>Details</strong></p></td></tr><tr><td data-highlight-colour="#b4f7ff" colspan="3" class="confluenceTd"><p><strong>6. Product Verification and Validation</strong></p></td></tr><tr><td data-highlight-colour="#bafaff" colspan="3" class="confluenceTd"><p><strong>6.1 Biocompatibility</strong></p></td></tr><tr><td class="confluenceTd"><p><strong>6.1.1 Biological safety risk assessment (either stand- alone or as a part of the risk management section)</strong></p></td><td class="confluenceTd"><p><strong> </strong>Provide a biological safety risk assessment for the device. As specified, this may either be a stand-alone document or part of the risk management section.</p></td><td class="confluenceTd"><p>Incomplete or not signposted -can’t find biological safety risk assessment.</p></td></tr><tr><td class="confluenceTd"><p><strong>6.1.2 Material characterisation test protocols and reports</strong></p></td><td class="confluenceTd"><p>Include all material characterisation test protocols and reports.</p><p>·       In particular, for devices specified in Annex I GSPR 10.4.1 containing or incorporating carcinogenic, mutagenic, or toxic to reproduction (“CMR”) substances of category 1A or 1B (in accordance with Part 3 of Annex VI to Regulation (EC) No 1272/2008), or substances having endocrine- disrupting properties must meet requirements in the MDR for justification of the presence of these substances. Specific labelling requirements must also be met for these substances (GSPR 10.4.5).</p><p>Where this information on CMR or endocrine-disrupting substances is provided by suppliers, manufacturers should confirm the completeness of this information and describe any additional testing or analysis performed to confirm the information and the presence of these substances.</p></td><td class="confluenceTd"><p>See <a href="OV-F1.-Biocompatibility_3342804.html" data-linked-resource-id="3342804" data-linked-resource-version="12" data-linked-resource-type="page">OV F1. Biocompatibility</a> </p><p>|ncomplete</p><p>To include 13485 certificates of manufacturers, test protocols and reports</p></td></tr><tr><td class="confluenceTd"><p><strong>6.1.3 Biocompatibility test protocols and reports</strong></p></td><td class="confluenceTd"><p><strong> </strong>The assessment should categorise the nature and duration of body contact for each component and identify any tests that are required or can be waived to establish evidence of compatibility. Justifications must be included for any tests that have been waived.</p></td><td class="confluenceTd"><p>Not started - to complete</p></td></tr><tr><td class="confluenceTd"><p><strong>6.1.4 Overall biological safety assessment</strong></p></td><td class="confluenceTd"><p>Biological safety assessments should be undertaken in accordance with ISO 10993-1. See Clause 7 of this standard for guidance with respect to appropriate report content for the overall biological safety assessment.</p><p>Biological safety assessments should include evidence of compliance for the finished device (including consideration of all materials and all manufacturing steps). It is not enough to simply state that devices have been manufactured from materials of well-established biological safety – an assessment which considers the impact of manufacturing and sterilisation processes, intended use must be provided.</p></td><td class="confluenceTd"><p>Not started - to complete</p></td></tr><tr><td class="confluenceTd"><p>6.1.5 CVs of the expert assessors involved in the biological safety assessment to establish competence</p></td><td class="confluenceTd"><p><strong> </strong>A justification should be provided regarding the qualifications of those involved in planning, executing, and analysing the biocompatibility assessment.</p></td><td class="confluenceTd"><p>Incomplete - to include</p></td></tr><tr><td data-highlight-colour="#b3f5ff" colspan="3" class="confluenceTd"><p><strong>6.2 Electrical safety and electromagnetic compatibility (EMC)</strong></p></td></tr><tr><td class="confluenceTd"><p>6.2.1 Electrical safety test protocols</p></td><td rowspan="2" class="confluenceTd"><p>Please provide the test protocols and reports for electrical safety testing, if applicable to the device.</p><p>Ensure the provided documentation clearly defines the ESSENTIAL PERFORMANCE of the device and is in line with the risk management documentation.</p><p>If a subset of devices has been selected for testing and this subset is intended to represent a larger range of devices, provide supporting documentation that demonstrates how the configurations that have been tested can be considered representative of the wider set of devices/configurations.</p></td><td class="confluenceTd"><p>See <a href="OV-F2.-Electrical-safety-and-electromagnetic-compatibility_3342818.html" data-linked-resource-id="3342818" data-linked-resource-version="11" data-linked-resource-type="page">OV F2. Electrical safety and electromagnetic compatibility</a> </p><p>Incomplete -to add scope of tests to F2.2, F2.3</p></td></tr><tr><td class="confluenceTd"><p>6.2.2 Electrical safety test reports</p></td><td class="confluenceTd"><p>See <a href="OV-F2.-Electrical-safety-and-electromagnetic-compatibility_3342818.html" data-linked-resource-id="3342818" data-linked-resource-version="11" data-linked-resource-type="page">OV F2. Electrical safety and electromagnetic compatibility</a> </p><p>Incomplete - to add reports to F2.3</p></td></tr><tr><td class="confluenceTd"><p>6.2.3 EMC test protocols</p></td><td rowspan="2" class="confluenceTd"><p>Please provide the test protocols and reports for EMC testing, if applicable to the device.</p><p>Ensure the provided documentation clearly defines the ESSENTIAL PERFORMANCE of the device and is in line with the risk management documentation.</p><p>If a subset of devices has been selected for testing and this subset is intended to represent a larger range of devices, provide supporting documentation that demonstrates how the configurations that have been tested can be considered representative of the wider set of devices/configurations.</p></td><td class="confluenceTd"><p><a href="OV-F2.-Electrical-safety-and-electromagnetic-compatibility_3342818.html" data-linked-resource-id="3342818" data-linked-resource-version="11" data-linked-resource-type="page">OV F2. Electrical safety and electromagnetic compatibility</a> </p><p>To add to f2.2</p></td></tr><tr><td class="confluenceTd"><p>6.2.4 EMC test reports</p></td><td class="confluenceTd"><p><a href="OV-F2.-Electrical-safety-and-electromagnetic-compatibility_3342818.html" data-linked-resource-id="3342818" data-linked-resource-version="11" data-linked-resource-type="page">OV F2. Electrical safety and electromagnetic compatibility</a> </p><p>Incomplete to add to F2.3</p></td></tr><tr><td data-highlight-colour="#bafaff" colspan="3" class="confluenceTd"><p><strong>6.3 Software Verification and Validation</strong></p></td></tr><tr><td class="confluenceTd"><p><strong> </strong>6.3.1 EN 62304 checklist</p></td><td class="confluenceTd"><p>Appropriate documentation is required if the medical devices are either stand-alone software or rely upon software. Provide a checklist against the requirements of EN 62304.</p><p>If medical device is stand-alone software, guidance for the qualification and classification of the software can be found in MDCG 2019-11 and Classification guidance documents.</p><p>There should be a rationale for why the software is a medical device and for its classification. If applicable, the software should be broken down into modules, some that have a medical purpose and some that do not. The modules with a medical purpose must comply with the requirements of the medical device directives and must carry the CE marking. The non-medical device modules are not subject to the requirements for medical devices.</p><p>Ensure all relevant harmonised and non-harmonised software standards have been considered. Ensure the software systems/modules/items have been assigned safety classifications based on standards.</p><p>Include documentation on the medical device software life-cycle processes implemented (e.g. software design/development, maintenance/change management, risk management, configuration management, problem resolution, verification, and validation processes). If software is intended to be used with mobile computing platforms, include information on specific features of mobile platforms demonstrating compliance with GSPR 17.3. <em>(Software referred to in this Section that is intended to be used in combination with mobile computing platforms shall be designed and manufactured taking into account the specific features of the mobile platform (e.g. size and contrast ratio of the screen) and the external factors related to their use (varying environment as regards level of light or noise).</em></p></td><td class="confluenceTd"><p>Need to update - RB to lead/complete</p></td></tr><tr><td class="confluenceTd"><p><strong> </strong>6.3.2 Software development plan</p></td><td class="confluenceTd"><p>Include software development procedures and the software development plan (SDP) detailing the activities completed as part of the software development lifecycle (e.g. software requirements specification, software architecture, software detailed design, software unit testing procedures/reports, software integration testing procedures/reports, and software system testing procedures/reports). Documentation related to the software maintenance and software configuration management processes should also be provided (e.g. software maintenance plan, configuration management plan).</p><p>Note:: Some documentation may or may not be required per the standards based on software system/module/item risk classification.</p></td><td class="confluenceTd"><p> See <a href="OV-C3.4.-Product-Manufacturing-Definitions-and-Procedures_54132737.html" data-linked-resource-id="54132737" data-linked-resource-version="40" data-linked-resource-type="page">OV C3.4. Product Manufacturing Definitions and Procedures</a> </p><p><a href="https://onalabs.atlassian.net/wiki/spaces/ONALABSQMS/pages/2753633/OLQMS-PRO012+-+Product+Lifecycle+SOP" data-linked-resource-id="2753633" data-linked-resource-version="31" data-linked-resource-type="page">OLQMS-PRO012 - Product Lifecycle SOP</a> </p><p>Review both documents for consistenct- variation and supply required documetns in technical file.</p><p>testing documentation to be included in technical file as per column 2</p></td></tr><tr><td class="confluenceTd"><p>6.3.3 Software requirements analysis</p></td><td class="confluenceTd"><p>Include the software requirements specification (SRS). An explanation regarding how the software requirements have been derived from higher level system requirements should be included and traceability to those higher-level requirements should be established. Risk controls implemented in software should also be included in the SRS. Software requirements should be clearly stated, unambiguous, and should be readily translatable into verification acceptance criteria.</p><p>NOTE: See EN 62304 Clause 5.2.2 for generally expected categories that should be covered in the software requirements specification.</p></td><td class="confluenceTd"><p> Incomplete.</p><p>Not documented or signposted.</p><p /><p>Needed for firmware and App.</p></td></tr><tr><td class="confluenceTd"><p><strong> </strong>6.3.5 Software detailed design</p></td><td class="confluenceTd"><p>For EN 62304 Software Safety Class ‘B’ and ‘C’ software, include the software detailed design (SDD). The software detailed design (SDD) represents a further refinement of the software architecture described in 6.3.4. The SDD should clearly identify the SOFTWARE UNITS that are derived from the SOFTWARE ITEMS specified in the software architecture. The SDD should provide details regarding the function and expected inputs and outputs of the SOFTWARE UNITS. In general, the SDD should provide enough detail to allow correct implementation of the SOFTWARE UNITS and their expected interfaces.</p></td><td class="confluenceTd"><p> Incomplete.</p><p>Not documented or signposted.</p></td></tr><tr><td class="confluenceTd"><p>6.3.6 Software unit implementation and verification</p></td><td class="confluenceTd"><p><strong> </strong>For EN 62304 Software Safety Class ‘B’ and ‘C’ software, include evidence of SOFTWARE UNIT verification. These may include unit test protocols/scripts and associated reports. Note that this type of testing is usually considered “white box” testing in that detailed knowledge of the underlying software code is usually required to properly design the unit verification tests. Where automated testing has been used to perform verification activities, include the test scripts and the test log results in the submission documentation.</p></td><td class="confluenceTd"><p> Please signpost and I’ll review</p></td></tr><tr><td class="confluenceTd"><p>6.3.7 Software integration and integration testing</p></td><td class="confluenceTd"><p><strong> </strong>For EN 62304 Software Safety Class ‘B’ and ‘C’ software, include evidence that software integration testing has been performed. Please note that this testing should be aimed at showing how the SOFTWARE ITEMS (which are internal to the SOFTWARE SYSTEM) function as expected when integrated together. Areas to investigate can include, for example, expected timing, functioning of internal and external interfaces, and testing under abnormal conditions/foreseeable misuse. This testing is typically not conducted on the final, compiled code and will normally make use of a test/simulation environment where various combinations of SOFTWARE ITEMS can be tested in isolation. It is permissible to combine software integration testing with software system testing (per 6.3.8 below). Where this strategy has been employed to cover the requirement to perform software integration testing, this should be clearly explained in the submission documentation. Where automated testing has been used to perform verification activities, include the test scripts and the test log results in the submission documentation.</p></td><td rowspan="2" class="confluenceTd"><p> Please signpost and I’ll review</p></td></tr><tr><td class="confluenceTd"><p>6.3.8 Software systems testing</p></td><td class="confluenceTd"><p><strong> </strong>Include the software system test protocol(s) and report(s). This testing should demonstrate that each of the software requirements (per 6.3.3) have been verified. It is expected that traceability between the software requirements and the software test cases/test procedures should be established. This testing is typically conducted on the final, compiled SOFTWARE SYSTEM. Input stimuli, expected outcomes, pass/fail criteria, and test procedures should be clearly established in the test documentation.</p><p>Where test failures or deviations have been encountered, these should be clearly documented and justified in the provided reports. Where automated testing has been used to perform verification activities, include the test scripts and the test log results in the submission documentation.</p></td></tr><tr><td class="confluenceTd"><p>6.3.9 Software release</p></td><td class="confluenceTd"><p>Include the <u>list of known residual anomalies</u>. The following information on each remaining anomaly should be included:</p><p>·     Unique Identifier</p><p>·     Brief description of the issue</p><p>·     Severity/Risk Level</p><p>·     Justification for why it is acceptable to release the software with the anomaly</p><p>Also include documentation showing how the released software was created (e.g. procedure and environment used create the released software). The final released software version number should be identified in this documentation. Documentation explaining how the released software is archived and how it can be reliably delivered (e.g. to the manufacturing environment or to the user of the software) should be included.</p></td><td class="confluenceTd"><p>Summarise in a release report if any known anomolies and signpost to this.</p></td></tr><tr><td class="confluenceTd"><p><strong> </strong>6.3.10 Software risk assessment</p></td><td class="confluenceTd"><p>Include software risk assessment documentation (e.g. software hazard analysis, software failure mode and effects analysis, fault tree analysis, traceability).</p><p>Note: Some documentation may or may not be required per the standards based on software system/module/item risk classification.</p></td><td class="confluenceTd"><p>  Please signpost and I’ll review</p></td></tr><tr><td class="confluenceTd"><p><strong> </strong>6.3.11 Cybersecurity documentation</p></td><td class="confluenceTd"><p>Include documentation related to the design and maintenance of the cybersecurity features of the medical device. Documentation should include the security risk management plan, security risk assessment, and verification/validation evidence for the identified security risk controls.</p><p>Threats and the associated protections needed to ensure the <strong>confidentiality</strong>, <strong>integrity</strong>, and <strong>availability </strong>of the data, function and services of the medical device should be considered. Documentation showing how cybersecurity threats are monitored and responded to as part of the post-market surveillance of the device should also be provided.</p><p>NOTE: See MDCG 2019-16 Guidance on Cybersecurity for medical devices.</p></td><td data-highlight-colour="#ffffff" class="confluenceTd"><p>Incomplete - Not started - no documentation in technical file.</p></td></tr><tr><td data-highlight-colour="#b3f5ff" colspan="3" class="confluenceTd"><p><strong>6.4 Stability including shelf life</strong></p></td></tr><tr><td class="confluenceTd"><p><strong>6.4.1 Stability/shelf-life validation protocols (to include both device and packaging performance)</strong></p></td><td rowspan="2" class="confluenceTd"><p>·     Shelf life is normally considered to be the time the device can be kept in the packaging prior to its first use. This is not the same as “Lifetime”.</p><p>·     Shelf-life testing is not restricted to the packaging. The device itself should be subject to shelf life testing, or a rationale provided to demonstrate why its characteristics are not expected to degrade over the claimed shelf life.</p><p>·     If shelf life testing is based on accelerated age testing, this should be accompanied by a plan for real time testing. Real time testing should be underway by the time documentation is submitted for review.</p><p>·     Extensions to shelf life for Class III devices and Class IIb implantable devices (non-WET) must be reported to BSI for review and certificate re- issue.</p><p>Shelf Life Validation should include:</p><p>·     Protocol (with acceptance criteria for each test performed) and appropriate test references;</p><p>·     A clear statement of the intended shelf life;</p><p>·     A clear statement defining the sterilisation status of the test samples (1X, 2X sterilised);</p><p>·     A summary of the accelerated aging parameters (temperature and humidity) and how the aging times were calculated;</p><p>·     A statement covering Real Time Aging plans;</p><p>·     A clear delineation of statistically significant sample quantities;</p><p>·     Actual physical/microbiological test data reports supporting the expiration date, or post aging, claim (peel testing, burst testing, dye testing, etc.);</p><p>·     A summary of the ship testing/transit simulation testing conducted and applicable test reports.</p></td><td class="confluenceTd"><p>Summarise in risk assessment/ test report or release report and signpost here please.</p><p>Should be consistent with materials characteristics.</p></td></tr><tr><td class="confluenceTd"><p><strong>6.4.2 Stability/shelf-life validation results and reports</strong></p></td><td class="confluenceTd"><p> Summarise in risk assessment/ test report or release report and signpost here please.</p><p>Should be consistent with materials/battery characteristics.</p></td></tr><tr><td data-highlight-colour="#bafaff" colspan="3" class="confluenceTd"><p><strong>6.5 Performance and Safety – Design Verification and Validations</strong></p></td></tr><tr><td class="confluenceTd"><p>6.5.1 Design control matrix</p></td><td class="confluenceTd"><p>A design verification / validation strategy document and / or summary of the outcomes should be provided. Verification / validation results should be provided for each design requirement. If compliance has been demonstrated without testing, an appropriate rationale should be provided.</p><p>For previously marketed or “legacy” devices applying for MDR certification, it is critical to provide an explanation and map of previously conducted testing and outline what testing is relevant to the current version of the device. If historic testing is referenced but a subsequent change was made and only some specifications were re-tested, please explain what test reports have superseded and should be reviewed for each relevant specification.</p></td><td class="confluenceTd"><p>Incomplete - need to add documents in F6</p><p>Documents in F3 need translating to English and moving to F6 where not related to calibration and cross referencing to design requirements.</p></td></tr><tr><td class="confluenceTd"><p><strong> </strong>6.5.2 Design requirements</p></td><td class="confluenceTd"><p><strong> </strong>Provide the documented design requirements for the device.</p></td><td class="confluenceTd"><p>See <a href="OV-C3.1.-Requirements-Specification_3342597.html" data-linked-resource-id="3342597" data-linked-resource-version="76" data-linked-resource-type="page">OV C3.1. Requirements Specification</a>  Incomplete - see comments in Part C summary</p></td></tr><tr><td class="confluenceTd"><p>6.5.3 Verification and validation plan</p></td><td class="confluenceTd"><p>Provide an overall plan for design verification and validation, if applicable.</p></td><td class="confluenceTd"><p>See F6.</p><p>Incomplete - needs plan</p></td></tr><tr><td class="confluenceTd"><p><strong> </strong>6.5.4 Verification protocols and results</p></td><td class="confluenceTd"><p>Test reports should document objectives, acceptance criteria, materials &amp; methods, results, protocol deviations, and conclusions.</p><p>If test results are considered representative for a group of devices (i.e. worst- case devices or comparative devices), then a justification for leveraging protocol(s) and report(s) should be provided.</p><p>Similarly, if testing has been undertaken on prototypes, previous generations of a device, or devices that otherwise do not represent the finished goods, a justification for the adequacy of this testing should be provided.</p><p>If multiple design verification / validation studies were conducted, please provide a flow chart or table that shows how the studies were conducted and highlight which study ultimately demonstrates that the design meets the product performance specifications.</p><p>For line extensions or devices based on “existing” devices, it may be possible to leverage data from testing undertaken on the existing devices. In this case, a rationale for the use of existing data must be provided, including:</p><p>·     Evidence of equivalence to the comparative devices – a table showing the similarities and differences greatly speeds the review process. Key things to consider include (but may not be limited to):</p><ul><li><p>Materials of construction</p></li></ul><ul><li><p>Indications for use</p></li></ul><ul><li><p>Methods of manufacturing</p></li></ul><ul><li><p>Key design features</p></li></ul><p>·     An evaluation of the impact of any differences on clinical safety, performance, and testing undertaken. The evaluation should support the conclusion that the new devices do not represent a worst case in terms of testing as compared to the devices tested.</p></td><td class="confluenceTd"><p>Incomplete - documentation needs to be added to section F to address requirements in column 2</p></td></tr><tr><td class="confluenceTd"><p><strong>6.5.5 Validation protocols and results</strong></p></td><td class="confluenceTd"><p>Please provide the protocols and results for design validation studies. See also 6.5.4 for guidance on appropriate contents and rationales.</p></td><td class="confluenceTd"><p>Incomplete - documentation needs to be added to section F to address requirements in column 2</p></td></tr><tr><td class="confluenceTd"><p><strong>6.5.6 Usability study protocols and results</strong></p></td><td class="confluenceTd"><p>Please provide the protocols and results for usability studies. See also 6.5.4 for guidance on appropriate contents and rationales.</p></td><td class="confluenceTd"><p>Incomplete - documentation needs to be added to section F to address requirements in column 2</p></td></tr><tr><td class="confluenceTd"><p>6.5.7 Evidence to support the device lifetime in use</p></td><td class="confluenceTd"><p>The lifetime of the device should be defined and considered relative to other parts of the dossier (e.g. risk management, clinical evaluation, PMS).</p><p>Product lifetime is normally considered as the time from first use until the device ceases to fulfil its intended use. This is not the same as “Shelf Life”.</p></td><td class="confluenceTd"><p>Incomplete - documentation needs to be added to section F to address requirements in column 2</p></td></tr><tr><td class="confluenceTd"><p>6.5.8 Sample Size Procedures</p></td><td class="confluenceTd"><p><strong>C</strong>learly define how sample sizes have been determined and the rationale/ justification for the sample sizes. If the rationale is documented in</p><p>a procedure provide the relevant procedure.</p></td><td class="confluenceTd"><p>Incomplete - documentation needs to be added to section F to address requirements in column 2 for all validations.</p></td></tr><tr><td data-highlight-colour="#b3f5ff" colspan="3" class="confluenceTd"><p>6.12 Packaging and Transport Testing</p></td></tr><tr><td class="confluenceTd"><p><strong>6.12.1 Packaging drawings and/or configurations</strong></p></td><td class="confluenceTd"><p>A complete packaging BoM and diagrams should be provided to illustrate how each device is packaged.</p></td><td class="confluenceTd"><p>Incomplete - no documentation in technical file to met requirements.</p></td></tr><tr><td class="confluenceTd"><p><strong>6.12.2 Packaging validation protocols</strong></p></td><td rowspan="2" class="confluenceTd"><p>Please provide the protocols and reports for packaging validation. For sterile devices, this must include the validations carried out towards establishing the sterile barrier. For non-sterile devices, evidence should be provided to establish that the packaging sufficiently protects the device in order to enable it to achieve its intended performance.</p><p>·     Packaging testing needs to be undertaken in accordance with relevant standards. If such standards are not used, alternate methods must be duly justified in terms of their suitability and state of the art.</p><p>·     If all packaging configurations / device combinations have not been tested, a rationale based on worst case (i.e. heaviest and lightest devices, sharp or pointy edges, etc.) should be provided.</p><p>·     Changes to packaging could potentially be considered as significant changes. For Class III devices and Class IIb implantable devices, these must be reported to BSI for review and certificate re-issue.</p></td><td class="confluenceTd"><p>Incomplete - no documentation in technical file to met requirements.</p></td></tr><tr><td class="confluenceTd"><p><strong> </strong></p><p><strong>6.12.3 Packaging validation reports</strong></p></td><td class="confluenceTd"><p>Incomplete - no documentation in technical file to met requirements.</p></td></tr><tr><td class="confluenceTd"><p><strong>6.12.4 Transit/transport testing protocols</strong></p></td><td rowspan="2" class="confluenceTd"><p>Provide protocols and reports for any transit/transportation testing conducted on the device to establish transit endurance and maintenance of the sterile barrier in case of sterile devices.</p></td><td class="confluenceTd"><p>Incomplete - no documentation in technical file to met requirements.</p></td></tr><tr><td class="confluenceTd"><p><strong>6.12.5 Transit/transport testing reports</strong></p></td><td class="confluenceTd"><p>Incomplete - no documentation in technical file to met requirements.</p><p>No sterile requirements- this component not applicable.</p></td></tr><tr><td data-highlight-colour="#b3f5ff" colspan="3" class="confluenceTd"><p><strong>6.15 Devices with a measuring or diagnostic function</strong></p></td></tr><tr><td class="confluenceTd"><p><strong>6.15.1 Protocols for tests associated with establishing the device limits of accuracy, precision, calibration</strong></p></td><td rowspan="2" class="confluenceTd"><p>If the device has a measuring function or diagnostic function, include test protocols and reports used for verifying or establishing the device limits of accuracy, precision, calibration etc</p><p>Refer to MEDDEV 2.1/5 for guidance on criteria that qualify a device as having a measuring function.</p></td><td class="confluenceTd"><p>See <a href="OV-F7.-Calibration_3342832.html" data-linked-resource-id="3342832" data-linked-resource-version="10" data-linked-resource-type="page">OV F7. Calibration</a> </p><p>Incomplete - protocols and reports need translating to English</p></td></tr><tr><td class="confluenceTd"><p><strong> 6.15.2 Reports for tests associated with establishing the device limits of accuracy, precision, calibration</strong></p></td><td class="confluenceTd"><p>Incomplete - protocols and reports need translating to English</p></td></tr><tr><td data-highlight-colour="#bafaff" colspan="3" class="confluenceTd"><p><strong> 6.16 Devices intended to be connected to other devices to operate as intended</strong></p></td></tr><tr><td class="confluenceTd"><p><strong> </strong>6.16.1 Protocols for tests associated with establishing the safety and performance of the device and the combination while connected to other devices and their interoperability</p></td><td rowspan="2" class="confluenceTd"><p>If the device is intended to be connected to other devices to operate as intended, include test protocols and reports that establish the safety and performance of the combination of devices including addressing their interoperability and any usability elements.</p></td><td class="confluenceTd"><p>Incomplete - evidence needed to establish protocols for wrist device and app connection performant.</p></td></tr><tr><td class="confluenceTd"><p>6.16.2 Reports for tests associated with establishing the safety and performance of device and the combination while connected to other devices and their interoperability</p></td><td class="confluenceTd"><p>Incomplete - evidence needed to establish protocols for wrist device and app connection performant.</p></td></tr></tbody></table></div><p /><h3 id="OVPartF:Pre-ClinicalInformation-3.DocumentDistribution">3. Document Distribution</h3><div class="table-wrap"><table data-table-width="760" data-layout="default" data-local-id="e5988672-ffc0-4732-9daf-ca0c38be5c42" class="confluenceTable"><colgroup><col style="width: 380.0px;"/><col style="width: 380.0px;"/></colgroup><tbody><tr><td class="confluenceTd"><p> </p></td><td class="confluenceTd"><p>Action/ information</p></td></tr><tr><td class="confluenceTd"><p>This document is intended for an internal and (restricted) external audience.</p><p>All external distribution of this document must be approved prior to circulation.</p></td><td class="confluenceTd"><p>Information</p><p> </p></td></tr></tbody></table></div><p> </p>
                    </div>

                    
                                                      
                </div>             </div> 
            <div id="footer" role="contentinfo">
                <section class="footer-body">
                    <p>Document generated by Confluence on Jun 30, 2025 15:56</p>
                    <div id="footer-logo"><a href="http://www.atlassian.com/">Atlassian</a></div>
                </section>
            </div>
        </div>     </body>
</html>
